Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members
AUTOR(ES)
Olayioye, Monilola A
FONTE
BioMed Central
RESUMO
ErbB (also termed HER) receptors are expressed in various tissues of epithelial, mesenchymal and neuronal origin, in which they are involved in the control of diverse biological processes such as proliferation, differentiation, migration and apoptosis. Furthermore, their deregulated expression has been implicated in many types of human cancers and is associated with poor clinical prognosis. Owing to the importance of ErbB proteins in both development and cellular transformation, a lot of attention has been drawn to the intracellular signals initiated by the engagement of this family of receptor tyrosine kinases. This review will focus on the membrane proximal events triggered by the ErbB receptor network and will address questions of how receptor heterodimerization may contribute to signal specification and diversification.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=138705Documentos Relacionados
- Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment
- Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
- Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
- Update on HER-2 as a target for cancer therapy: Alternative strategies for targeting the epidermal growth factor system in cancer
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer